» Articles » PMID: 32573730

Underestimation of COVID-19 Cases in Japan: an Analysis of RT-PCR Testing for COVID-19 Among 47 Prefectures in Japan

Overview
Journal QJM
Specialty General Medicine
Date 2020 Jun 24
PMID 32573730
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Under the unique Japanese policy to restrict reverse transcriptase-polymerase chain reaction (RT-PCR) testing against severe acute respiratory syndrome coronavirus 2, a nationwide number of its confirmed cases and mortality remains to be low. Yet the information is lacking on geographical differences of these measures and their associated factors.

Aim: Evaluation of prefecture-based geographical differences and associated predictors for the incidence and number of RT-PCR tests for coronavirus disease 2019 (COVID-19).

Design: Cross-sectional study using regression and correlation analysis.

Methods: We retrieved domestic laboratory-confirmed cases, deaths and the number of RT-PCR testing for COVID-19 from 15 January to 6 April 2020 in 47 prefectures in Japan, using publicly available data by the Ministry of Health, Labour and Welfare. We did descriptive analyses of these three measures and identified significant predictors for the incidence and RT-PCR testing through multiple regression analyses and correlates with the number of deaths through correlation analysis.

Results: The median prefectural-level incidence and number of RT-PCR testing per 100 000 population were 1.14 and 38.6, respectively. Multiple regression analyses revealed that significant predictors for the incidence were prefectural-level population (P < 0.001) and the number of RT-PCR testing (P = 0.03); and those for RT-PCR testing were the incidence (P = 0.025), available beds (P = 0.045) and cluster infections (P = 0.034).

Conclusion: Considering bidirectional association between the incidence and RT-PCR testing, there may have been an underdiagnosed population for the infection. The restraint policy for RT-PCR testing should be revisited to meet the increasing demand under the COVID-19 epidemic.

Citing Articles

Excess Deaths in Korea During the COVID-19 Pandemic: 2020-2022.

Im S, Shin J, Lee D J Prev Med Public Health. 2024; 57(5):480-489.

PMID: 39384173 PMC: 11471339. DOI: 10.3961/jpmph.24.254.


Fukuchi-Manabe Score for Infection Control Measures During the Very Early COVID-19 Pandemic Period When Access to Reverse Transcription-Polymerase Chain Reaction Testing Was Poor in Japan: A Single-Center Observational Prospective Cohort Study.

Fukuchi T, Oyama-Manabe N, Sugawara H Cureus. 2024; 16(2):e54748.

PMID: 38523950 PMC: 10960966. DOI: 10.7759/cureus.54748.


A measure to estimate the risk of imported COVID-19 cases and its application for evaluating travel-related control measures.

Kang H, Min K, Jeon S, Lee J, Cho S Sci Rep. 2022; 12(1):9497.

PMID: 35681085 PMC: 9178220. DOI: 10.1038/s41598-022-13775-0.


Preclinical Efficacy and Clinical Feasibility of a Novel Aerosol-Exposure Protection Mask for Esophagogastroduodenoscopy.

Makiguchi M, Abe S, Okagawa Y, Nonaka S, Suzuki H, Yoshinaga S Clin Endosc. 2021; 55(2):226-233.

PMID: 34905818 PMC: 8995999. DOI: 10.5946/ce.2021.178-IDEN.


Reduced mortality during the COVID-19 outbreak in Japan, 2020: a two-stage interrupted time-series design.

Onozuka D, Tanoue Y, Nomura S, Kawashima T, Yoneoka D, Eguchi A Int J Epidemiol. 2021; 51(1):75-84.

PMID: 34718594 PMC: 8856001. DOI: 10.1093/ije/dyab216.


References
1.
Lauer S, Grantz K, Bi Q, Jones F, Zheng Q, Meredith H . The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; 172(9):577-582. PMC: 7081172. DOI: 10.7326/M20-0504. View

2.
Anderson R, Heesterbeek H, Klinkenberg D, Hollingsworth T . How will country-based mitigation measures influence the course of the COVID-19 epidemic?. Lancet. 2020; 395(10228):931-934. PMC: 7158572. DOI: 10.1016/S0140-6736(20)30567-5. View

3.
Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T . Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan. QJM. 2020; 113(11):785-786. PMC: 7313848. DOI: 10.1093/qjmed/hcaa182. View